Biotech industry faced challenges in 2024, but young firms hold potential; Avadel Pharmaceuticals a buy.

From Investing.com: 2025-01-21 11:53:00

Despite economic strength, the biotech industry faced challenges in 2024. The iShares Biotechnology ETF ended down by 1.2% by January 17, 2025, due to high borrowing costs and healthcare sector changes. Young biotech firms hold potential for investors with blockbuster drug approvals. Avadel Pharmaceuticals saw a plunge in shares despite revenue growth, presenting a buy opportunity with strong cash reserves. Sana Biotechnology doubled in value after revealing groundbreaking allogeneic transplant study data, potentially revolutionizing type 1 diabetes treatment. ADMA Biologics experienced significant growth in revenue and net income in 2024, aiming for $1 billion annual revenue before 2030.



Read more at Investing.com: There May Still Be Time to Get In on These 3 Trending Biotechs